Last edition
News about "A1C reduction"
Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes
Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.
A1C Reduction | 10/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members